MaxCyte IPO Presentation Deck

Summary and Outlook for 2021+ July 2021 16 ос Prepare / Isolate EB R Culture / Expand 2020 Achievements Wash QC EB R Concentrate Reported 21% revenue growth despite a challenging COVID environment Continued to expand capabilities in engineering new cell types Built our PA portfolio with the introduction of new PAS Expansion of strategic partnerships; 4 in 2020/early 2021; strategic partnership pipeline is the largest it has been Made the decision to re-allocate CARMA™ funding to Life Sciences to accelerate growth 2 3 R 4 Culture CONFIDENTIAL QC R Cryopreserve 1 Strong top-line growth driven by cell therapy Invest in manufacturing expansion/automation Continue to launch new products to address customer needs and expand into new applications Thaw / Dose 2021+ Goals QC Working towards commercializing the large-scale platform (VLx) and associated consumables under the EXPERT brand Future investments in upstream and downstream technologies in cell therapy through partnerships or acquisitions 5 16

View entire presentation